Published on 29 Aug 2023 on Simply Wall St. via Yahoo Finance

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Shareholders in Lyell Immunopharma, Inc. (NASDAQ:LYEL) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The revenue forecast for this year has experienced a facelift, with analysts now much more optimistic on its sales pipeline.

Following the latest upgrade, the four analysts covering Lyell Immunopharma provided consensus estimates of US$115k revenue in 2023, which would reflect a sizeable 100% decline on its sales over the past 12 months. Per-share losses are expected to explode, reaching US$1.05 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$92k and losses of US$1.06 per share in 2023. So there's definitely been a change in sentiment in this update, with the analysts upgrading this year's revenue estimates, while at the same time holding losses per share steady.

See our latest analysis for Lyell Immunopharma